Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.

British journal of clinical pharmacology - 1 Jul 2000

Ford G A, Wood S M, Daly A K

Abstract excerpt

AIMS: Terodiline has concentration dependent QT prolonging effects and thus the potential for cardiotoxicity. Pharmacogenetic variation in terodiline metabolism could be responsible for cardiotoxicity. We sought to determine whether CYP2D6 (debrisoquine hydroxylase) or CYP2C19 (S-mephenytoin hydroxylase) status is a risk factor for terodiline cardiotoxicity. METHODS: Using the UK Yellow Card scheme to identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Debrisoquin

Share to Mixed Function Oxygenases

Share to Tachycardia, Ventricular

Share to Torsades de Pointes

Source

Open in PubMed Open full text

Identifiers

PMID: 10886124
DOI: 10.1046/j.1365-2125.2000.00230.x
PMCID: PMC2014965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.PMID 10886124Read ↗

Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions.Semantic proximity Read ↗

Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.Semantic proximity Read ↗

Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.Semantic proximity Read ↗

An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effectsSemantic proximity Read ↗

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.Semantic proximity Read ↗

Association of the NOS1AP rs10494366 Genetic Variant With Drug-Induced QT Prolongation.Semantic proximity Read ↗

CYP2C19 genetics in fatal carisoprodol intoxications.Semantic proximity Read ↗

Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.Semantic proximity Read ↗

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.Semantic proximity Read ↗

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.